ライフサイエンスコーパス: gait speed

1 a 5-m walk time longer than 6 seconds (slow gait speed).

2 ex, and hypertension significantly explained gait speed.

3 strumental activity of daily living, or slow gait speed.

4 exhaustion, low physical activity, and slow gait speed.

5 ressive symptoms were associated with slower gait speed.

6 ociated with a 0.01 +/- 0.00-m/s decrease in gait speed.

7 cise resulted in the greatest improvement in gait speed.

8 body composition and age-related decline in gait speed.

9 sion scale) were also associated with slower gait speed.

10 scle area is also predictive of a decline in gait speed.

11 t and during gait, when they correlated with gait speed.

12 ss rest and gait, and did not correlate with gait speed.

13 volume, and small-vessel disease but not on gait speed (0.85 vs 0.92 m/s, P = .01) or proportion of

14 le lowlanders walked on a treadmill at seven gait speeds (0.67-1.83 m s(-1)) on a level gradient unde

15 1.05 per 1-year increase [1.01-1.08]), lower gait speed (1.15 per 0.1-m/s slower gait [1.06-1.24]), l

16 The primary outcome measures were gait speed (6-minute walk), cardiovascular fitness (peak

17 morbidity (OR, 1.03 per 0.1-m/s decrease in gait speed; 95% CI, 1.00-1.05).

18 mortality (OR, 1.11 per 0.1-m/s decrease in gait speed; 95% CI, 1.07-1.16).

19 monary function had significantly slower 4-m gait speed (all but one p < 0.05).

20 sociation between continuous and categorical gait speed and 30-day all-cause mortality before and aft

21 the global and regional associations between gait speed and Abeta in the whole sample and the CN subs

22 The inverse association between gait speed and depressive symptoms appears to be bidirec

23 Several regional associations between gait speed and PiB uptake withstood relevant adjustments

24 receiver operating characteristic analysis, gait speed and TUAG more strongly predicted 3-year morta

25 l [CI], 0.30 to 0.59, per 1m/sec increase in gait speed) and the two-year lagged association fully (O

26 ysical frailty (defined on the basis of slow gait speed) and were followed up with monthly telephone

27 tivity level, weakness, exhaustion, and slow gait speed), and incident CVD as onset of coronary arter

28 es, pacemaker use, atrial fibrillation, slow gait speed, and nonfemoral access were significantly ass

29 tcomes (four-step stair climbing time, usual gait speed, and time to rise five times from a chair wit

30 After adjustment, each 0.1-m/s decrement in gait speed associated with a 26% higher risk for death,

31 Gait speed can be used to refine estimates of operative

32 Gait speed changes were consistent with reported changes

33 Gait speed, cognitive index, conventional MRI markers of

34 d including age, sex, vascular risk factors, gait speed, cognitive index, MRI, and diffusion measures

35 tion of short-latency afferent inhibition to gait speed, controlling for age, posture and gait sympto

36 Each 0.2-m/s decrease in gait speed corresponded to an 11% increase in 30-day mor

37 adults aged 65 years or older with baseline gait speed data, followed up for 6 to 21 years.

38 thigh intermuscular fat predicted the annual gait-speed decline (+/-SE) in both men and women (-0.01

39 nly body-composition measures that predicted gait-speed decline in men and women combined.

40 ntermuscular fat are important predictors of gait-speed decline, implying that fat infiltration into

41 tle research has identified risk factors for gait-speed decline.

42 Gait speed declined by 0.06 +/- 0.00 m/s over the 4-y pe

43 res (>80th percentile) were more impaired by gait speed, difficulty with Instrumental Activities of D

44 -Blood pressure, gait speed, digit symbol substitution test, and the Cent

45 red on a scale from 0 to 5 by grip strength, gait speed, exhaustion, shrinkage, and physical activity

46 ition was an independent predictor of slower gait speed, explaining 37% of variability.

47 ification of frail patients with the slowest gait speeds facilitates preprocedural evaluation and ant

48 d side ([Formula: see text] = 0.029), faster gait speed ([Formula: see text] = 0.018) and lower IADL

49 predictive scale in each domain was: 5-meter gait speed >/=6 seconds as a measure of frailty (odds ra

50 Physical frailty (defined as gait speed >10 seconds on the rapid gait test) was asses

51 climbing test, 6-min walking distance, fast gait speed, hand grip strength, and isometric leg extens

52 -step tests), chair rise with arms, and fast gait speed improved significantly from baseline to week

53 of SVD-related morphologic brain changes on gait speed in addition to age, sex and hypertension inde

54 r coupling in the middle cerebral artery and gait speed in elderly individuals with impaired cerebral

55 To examine the association between Abeta and gait speed in elderly individuals without dementia and t

56 ther amyloid-beta (Abeta) is associated with gait speed in elderly individuals without dementia and w

57 influence the association between Abeta and gait speed in elderly individuals without dementia.

58 l Abeta deposition is associated with slower gait speed in elderly individuals without dementia; howe

59 y mechanisms responsible for preservation of gait speed in elderly people with cerebrovascular diseas

60 al significant and independent predictors of gait speed in the regression model.

61 was accompanied by significant increases in gait speed, incline on the treadmill, the maximal volunt

62 nee strength, power, and quality and the 4-m gait speed increased similarly in both groups.

63 Functional status was assessed by gait speed, instrumental activities of daily living (IAD

64 The 4-m gait speed is a reliable, valid, and responsive measure

65 Gait speed is an independent predictor of adverse outcom

66 In older adults, every 0.1-m/s slower gait speed is associated with a 12% higher mortality.

67 toms and physical performance measured using gait speed is bidirectional.

68 Gait speed is independently associated with 30-day morta

69 prediction of mortality, an older age, lower gait speed, lower gray matter volume, and greater global

70 Poor performance was defined as a gait speed <1 m/s after 9 y of follow-up (n = 1542).

71 n models to analyse repeated measurements of gait speed (m/sec) and elevated depressive symptoms (def

72 ction between cognitive task performance and gait speed may differ according to walking intensity.

73 Physical performance measures, such as gait speed, might help account for variability, allowing

74 The estimated 4-m gait speed minimal important difference was 0.03-0.06 m/

75 Therefore, exercise can improve gait speed, muscle strength, and fitness for patients wi

76 Secondary outcome measures were gait speed, number of falls, daily activity (Barthel ind

77 women; and 79.8%, white; and had a mean (SD) gait speed of 0.92 (0.27) m/s.

78 m least active to most active had an average gait speed of 4.0, 4.2, 4.3, and 4.5 feet/second, respec

79 mpound B (PiB) positron emission tomography, gait speed over 4.57 m (15 ft), and cognition on the Min

80 arkinson's disease had significantly reduced gait speed (P = 0.002), stride length (P = 0.008) and st

81 (p = 0.03), exhaustion (p = 0.01), and slow gait speed (p = 0.03) were significantly associated with

82 djustment for covariates (including previous gait speed) partially explained both the concurrent (bet

83 edicted 10-year survival across the range of gait speeds ranged from 19% to 87% in men and from 35% t

84 isk of mortality and the surgical procedure, gait speed remained independently predictive of operativ

85 re significantly associated with the 4-meter gait speed (rs928874, p = 5.61 x 10(-8); rs1788355, p =

86 ong the physical domains of pre-frailty, low gait speed seems to be the best predictor of future CVD.

87 significant associations were found between gait speed, short-latency afferent inhibition, age and p

88 Furthermore, 4-m gait speed significantly predicted future hospitalizatio

89 Compared with patients in the fastest gait speed tertile (>1.00 m/s), operative mortality was

90 ions for clinical studies evaluating the 4-m gait speed test in acute respiratory distress syndrome s

91 The 5-m gait speed test was performed in 15171 patients aged 60

92 inically small, improvements in mobility and gait speed that are not sustained after treatment ends.

93 We compared handgrip strength, usual gait speed, timed up and go (TUAG), and 6-minute walking

94 Adding gait speed to a model that included estimated GFR signif

95 Addition of gait speed to the Society of Thoracic Surgeons predicted

96 ntegrating a measure of frailty, such as 5-m gait speed, to better capture the heterogeneity of the o

97 The overall median gait speed was 0.63 m/s (25th-75th percentile, 0.47-0.79

98 Gait speed was 2.6 m/min (0.30-4.95) higher in the treat

99 Gait speed was also predictive of the composite outcome

100 Predicted survival based on age, sex, and gait speed was as accurate as predicted based on age, se

101 Four-meter gait speed was assessed at 6- and 12-month follow-up (AR

102 Relative gait speed was assessed with trunk accelerometry.

103 Slower gait speed was associated with elevated depressive sympt

104 Gait speed was associated with survival in all studies (

105 of individual data from 9 selected cohorts, gait speed was associated with survival in older adults.

106 Cognitive task score and gait speed were measured.

107 ociated with a 0.01 +/- 0.00-m/s decrease in gait speed, whereas every 16.92-cm(2) decrease in thigh

108 ores do not include frailty assessments (eg, gait speed), which are of particular importance for pati

109 final model explained 72% of variability in gait speed with only short-latency afferent inhibition a

110 We assessed the association of 5-m gait speed with outcomes in a cohort of 8039 patients wh

111 Survival increased across the full range of gait speeds, with significant increments per 0.1 m/s.